Related Experiment Video
Updated: Jun 4, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Incretin-based therapies for type 2 diabetes: a nurse's perspective
1Diabetes Centre, Selly Oak Hospital, University Hospital Birmingham NHS Foundation Trust.
British Journal of Nursing (Mark Allen Publishing)
|March 2, 2011
Summary
New incretin therapies offer improved treatment options for Type 2 diabetes (T2D) in the UK. This review explores the clinical evidence and benefits of these novel approaches for patients and healthcare providers.
Area of Science:
- Endocrinology
- Pharmacology
- Public Health
Background:
- Type 2 diabetes (T2D) presents a growing public health challenge in the UK, characterized by increasing prevalence and earlier onset.
- Existing T2D treatments present challenges for patient adherence and clinical management, necessitating the exploration of novel therapeutic strategies.
Purpose of the Study:
- To review the clinical evidence for incretin-based therapies in the context of UK prescribing guidelines.
- To evaluate the potential benefits of incretin therapies for patients diagnosed with Type 2 diabetes.
Main Methods:
- Systematic review of clinical studies and guidelines related to incretin therapies.
- Analysis of efficacy, safety, and patient-reported outcomes for incretin-based treatments.
Main Results:
- Incretin therapies demonstrate significant potential in improving glycemic control and offering alternative treatment pathways for T2D.
- Evidence supports the clinical utility of these agents within the UK healthcare system.
Conclusions:
- Increased awareness and understanding of incretin therapies can empower diabetes nurses to broaden treatment options for T2D patients.
- Incretin therapies represent a valuable addition to the management of Type 2 diabetes, addressing limitations of current treatments.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...